Literature DB >> 15258980

Antigenic characterisation of influenza B virus with a new microneutralisation assay: comparison to haemagglutination and sequence analysis.

Filippo Ansaldi1, Sabrina Bacilieri, Daniela Amicizia, Laura Valle, Federica Banfi, Paolo Durando, Laura Sticchi, Roberto Gasparini, Giancarlo Icardi, Pietro Crovari.   

Abstract

Although the haemagglutination inhibition assay is considered the "gold standard" for antigenic characterisation of influenza viruses, some limitations of this technique are well known. A new microneutralisation assay, as a tool for antigenic characterisation of influenza B viruses, has been standardised and its performance evaluated in comparison with the haemagglutination inhibition test in the light of molecular characterisation of the haemagglutinin. Twelve B viruses belonging to the two lineages and the four sub-lineages discriminated by phylogenetic analysis of HA were tested. The microneutralisation assay clearly distinguishes viruses belonging to different lineages and, in addition, discriminates strains belonging to different sub-lineages that are poorly or not discriminated using the haemagglutination inhibition test. This new microneutralisation assay could provide a useful tool for antigenic characterisation of circulating influenza viruses and contribute, together with the haemagglutination inhibition test and sequence analysis of the haemagglutinin and neuraminidase, in the choice of the strain for use in vaccine composition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15258980     DOI: 10.1002/jmv.20157

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses.

Authors:  Filippo Ansaldi; Sabrina Bacilieri; Federica Banfi; Paolo Durando; Laura Sticchi; Giancarlo Icardi; Roberto Gasparini
Journal:  Clin Vaccine Immunol       Date:  2006-01

2.  Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability.

Authors:  Filippo Ansaldi; Andrea Orsi; Daniela de Florentiis; Valentina Parodi; Emanuela Rappazzo; Martina Coppelli; Paolo Durando; Giancarlo Icardi
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

3.  Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies.

Authors:  Francesca Ferrara; Joanne Marie M Del Rosario; Kelly A S da Costa; Rebecca Kinsley; Simon Scott; Sasan Fereidouni; Craig Thompson; Paul Kellam; Sarah Gilbert; George Carnell; Nigel Temperton
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

4.  The Molecular Epidemiology and Evolutionary Dynamics of Influenza B Virus in Two Italian Regions during 2010-2015: The Experience of Sicily and Liguria.

Authors:  Fabio Tramuto; Andrea Orsi; Carmelo Massimo Maida; Claudio Costantino; Cecilia Trucchi; Cristiano Alicino; Francesco Vitale; Filippo Ansaldi
Journal:  Int J Mol Sci       Date:  2016-04-13       Impact factor: 5.923

5.  Fifteen years of epidemiologic, virologic and syndromic influenza surveillance: A focus on type B virus and the effects of vaccine mismatch in Liguria region, Italy.

Authors:  Cecilia Trucchi; Cristiano Alicino; Andrea Orsi; Chiara Paganino; Ilaria Barberis; Federico Grammatico; Paola Canepa; Emanuela Rappazzo; Bianca Bruzzone; Laura Sticchi; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452

Review 6.  Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.

Authors:  Claudia Maria Trombetta; Daniele Perini; Stuart Mather; Nigel Temperton; Emanuele Montomoli
Journal:  Vaccines (Basel)       Date:  2014-10-13

7.  Integrating influenza antigenic dynamics with molecular evolution.

Authors:  Trevor Bedford; Marc A Suchard; Philippe Lemey; Gytis Dudas; Victoria Gregory; Alan J Hay; John W McCauley; Colin A Russell; Derek J Smith; Andrew Rambaut
Journal:  Elife       Date:  2014-02-04       Impact factor: 8.140

8.  Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20-64 years, 2007-2011.

Authors:  Heath A Kelly; Sheena G Sullivan; Kristina A Grant; James E Fielding
Journal:  Influenza Other Respir Viruses       Date:  2012-10-19       Impact factor: 4.380

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.